SUBSCRIBE
Drivetime Radio

Drivetime Specialty is a free educational audio program covering a range of topics relevant to various medical specialists & physicians. Listen to our experienced medical broadcasters, moderating engaging discussions with leading experts.

Current disciplines include:

  • Dentist, hosted by Dr Patrick Meaney
  • Epilepsy, hosted by Prof Mark Cook, Neurologist, Melbourne
  • Endocrinology, hosted by Prof Rod Baber, Obstetrician & Gynaecologist, Sydney
  • Neurology, hosted by Prof Mark Cook, Neurologist, Melbourne
  • Ophthalmology, hosted by Prof Paul Mitchell, Ophthalmologist, Sydney
  • Psychiatry, hosted by Prof Malcolm Hopwood, Psychiatrist, Melbourne
  • Respiratory, hosted by Prof John Upham, Respiratory Physician, Brisbane
  • Haematology, hosted by Prof Christ Ward, Haematologist, Royal North Shore Hospital, Sydney
  • More disciplines coming soon…

A podcast of the specialty series is available to download, providing a time efficient form of communication that’s convenient and easy to consume. Click here for podcast download instructions You can also listen online – search by your area of interest to filter interviews relevant to you.

Interviews are provided exclusively for Australian healthcare professionals. Subscribe for free today to access all programs.

Search Interviews

By area of interest:

Specialty Interviews

Endo.2A different progestogen only pill option
00:00
Preview
10 seconds
Show more information

Until now, for patients with cardiovascular risk factors, postpartum mothers, or for those in whom their doctors want to avoid oestrogen, there have been limited oral contraceptive options to offer. In this interview we will be exploring new progesterone only contraceptive options for women.

Hosted by

Professor Rod Baber

Interviewees

  • A/Prof Deborah Bateson, Medical Director, Family Planning New South Wales A/Prof Deborah Bateson, Medical Director, Family Planning New South Wales
Endo.1How can we safely lower the rate of pre-term birth?
00:00
Preview
10 seconds
Show more information

Preterm birth is the single greatest cause of death in young children in Australia. It is also a major cause of disabilities including deafness, blindness, cerebral palsy and learning difficulties. While this information is not new to us, there is a general lack of awareness about the importance of preterm birth in the community. Over the last twenty years the rates of preterm births have been rising in Australia, making this issue more pressing. In this interview we discuss ways we can safely lower the rate of preterm births.

Hosted by

Professor Rod Baber

Interviewees

  • Dr Chris Lehner, Australian Preterm Birth Prevention AllianceDr Chris Lehner, Australian Preterm Birth Prevention Alliance
Oph.1The promise of retinal gene therapy
00:00
Preview
10 seconds
Show more information

In recent years, there have been significant advances in gene therapy for retinal disease including progress in targeting particular retinal cell types and the development of more efficient gene therapy vectors. Advances in the technology and in our understanding of the genetic basis of retinal diseases suggests we may be at the dawn of a new therapeutic era in ophthalmology. In this interview we discuss cutting edge research into novel gene therapy strategies.

Hosted by

Associate Professor Peter Van Wijngaarden

Interviewees

  • Matthew Simunovic, Vitreoretinal Surgeon at the Sydney Eye Hospital & Associate Professor at the University of SydneyMatthew Simunovic, Vitreoretinal Surgeon at the Sydney Eye Hospital & Associate Professor at the University of Sydney
Psy.9.2What’s new in The Clinical Practice Guidelines for Mood Disorders?
00:00
Preview
10 seconds
Show more information

The Royal Australian New Zealand College of Psychiatrists released updated clinical practice guidelines for mood disorders in 2021. In this interview we’re talking with one of the co-authors of the guidelines, about the changes with particular emphasis on the sometimes controversial additions, and new sections such as the seven ‘Choice’ antidepressants, circadian function as a potential intervention target, and moving away from the term treatment-resistant depression.

Hosted by

Professor Malcolm Hopwood

Interviewees

  • Prof. Philip Boyce, Professor Emeritus of Psychiatry, the University of SydneyProf. Philip Boyce, Professor Emeritus of Psychiatry, the University of Sydney
Psy.9.1Tools and treatments that can improve cognitive functioning in people with schizophrenia
00:00
Preview
10 seconds
Show more information

It’s well established that cognitive functioning can be significantly affected in people with all mental illnesses and cognitive impairment is one of the known symptoms of schizophrenia. Cognitive deficits significantly impact our patients’ overall functioning, quality of life, but earlier treatment and functional recovery may help improve outcomes. In this interview we talk about cognitive impairment in mental illness, the value of cognitive assessment tools and treatments that can improve cognitive functioning in people with schizophrenia, with a focus on lurasidone.

Hosted by

Professor Malcolm Hopwood

Interviewees

  • Prof. Bernhard Baune, Head of the Mental Health Department, University Münster, GermanyProf. Bernhard Baune, Head of the Mental Health Department, University Münster, Germany
Ren.1AV fistula maintenance and treatments for access flow dysfunction (30 mins)
00:00
Preview
10 seconds
Show more information

Renal: Haemodialysis remains the most common type of kidney replacement therapy, with more than 2 million people on haemodialysis worldwide. Arteriovenous fistulas created with native vessels are considered the vascular access of choice for haemodialysis and maintaining the integrity of the fistula is a key component of management. Vascular access dysfunction is a major cause of morbidity, mortality and excess healthcare costs, and maintaining effective, functioning vascular access to provide adequate dialysis is an ongoing challenge. In this interview we discuss AV fistula maintenance, including the use of plastic cannulas versus metal needles, as well as treatments for access flow dysfunction.
30 minute listen

Hosted by

Dr David Voss

Interviewees

  • A/Prof. Andrew Holden, Director of Interventional Radiational Services, Auckland City Hospital,A/Prof. Andrew Holden, Director of Interventional Radiational Services, Auckland City Hospital,
  • Diane Du Toit, Clinical Nurse Consultant, Hervey Bay, QLDDiane Du Toit, Clinical Nurse Consultant, Hervey Bay, QLD
Psy.8.1Major depressive disorder & prioritising outcomes that patients prioritise: Quality of life, functioning & positive mental health (19 mins)
00:00
Preview
10 seconds
Show more information

Psychiatry: When we treat patients with major depressive disorder, we do achieve remission in a significant proportion, but many patients may continue to have residual symptoms such as tiredness, the inability to concentrate and ongoing feelings of a lack of pleasure and emotional attachment in their lives. These may affect a patient’s ability to function in the workplace, at home while studying and can reduce their quality of life. In this interview we discuss the impact of residual symptoms. 19-minute listen

Hosted by

Professor Malcolm Hopwood

Interviewees

  • Prof. Roger McIntyre, Professor of Psychiatry and Pharmacology, University of Toronto, CanadaProf. Roger McIntyre, Professor of Psychiatry and Pharmacology, University of Toronto, Canada
Psy.8.2Why can’t I feel anything? Addressing anhedonia and emotional blunting in patients with MDD (28 mins)
00:00
Preview
10 seconds
Show more information

Psychiatry: We’ve become increasingly aware about the importance and impacts of residual symptoms such as tiredness, anhedonia and cognitive symptoms in patients being treated for major depressive disorder1. In this interview we discuss how we can better manage residual symptoms in our patients. 28 minute listen

Hosted by

Professor Malcolm Hopwood

Interviewees

  • Prof. Andrea Fagiolini, Dept of Molecular Medicine, Division of Psychiatry, University of Siena, School of Medicine, Siena, ItalyProf. Andrea Fagiolini, Dept of Molecular Medicine, Division of Psychiatry, University of Siena, School of Medicine, Siena, Italy
Hae.1Changing tides in the current management of relapsed refractory multiple myeloma: Complexities & challenges (27 mins)
00:00
Preview
10 seconds
Show more information

Haematology: The treatment landscape in multiple myeloma has changed considerably over the past few years, resulting in a significant shift in the treatment paradigm in the relapsed/refractory multiple myeloma space. Join myeloma expert Prof. Hang Quach as she discusses the implications of these changes to current guidelines and treatment practices, and shares her thoughts on the optimal use of new therapies moving forward. 26-minute listen

Hosted by

Professor Christopher Ward

Interviewees

  • Prof Hang Quach, Director of Haematology, St Vincent’s Hospital, Melbourne, VictoriaProf Hang Quach, Director of Haematology, St Vincent’s Hospital, Melbourne, Victoria
Hae.2What do the recent PBS changes mean in the world of refractory and relapsed multiple myeloma? (30 mins)
00:00
Preview
10 seconds
Show more information

Haematology: Earlier this year, the PBAC expanded the listing for carfilzomib to include once-weekly dosing in addition to twice-weekly dosing, in patients with relapsed/refractory multiple myeloma. In addition, daratumumab achieved its first listing, in combination with bortezomib and dexamethasone. Join haematologist Dr Wojt Janowski as he discusses these recent changes to the PBS, and learn how he manages relapsed/refractory myeloma patients in his clinic.  30-minute listen

Hosted by

Professor Christopher Ward

Interviewees

  • Dr Wojt Janowski, Haematologist, NewcastleDr Wojt Janowski, Haematologist, Newcastle

Search Interviews

By area of interest:

Exclusively for Australian healthcare professionals
×

Tap the share icon ios share icon and select 'Add to Home Screen' to add the site to your home screen for quick access!